ACIU | AC Immune SA

Index- P/E- EPS (ttm)-0.92 Insider Own53.88% Shs Outstand83.39M Perf Week11.90%
Market Cap193.40M Forward P/E- EPS next Y-0.33 Insider Trans0.00% Shs Float43.67M Perf Month27.03%
Income-76.70M PEG- EPS next Q-0.20 Inst Own18.40% Short Float / Ratio0.59% / 3.24 Perf Quarter-2.08%
Sales4.30M P/S44.98 EPS this Y13.00% Inst Trans1.19% Short Interest0.26M Perf Half Y-7.84%
Book/sh2.03 P/B1.16 EPS next Y41.90% ROA-35.70% Target Price10.67 Perf Year-24.44%
Cash/sh1.41 P/C1.66 EPS next 5Y- ROE-38.80% 52W Range1.68 - 3.90 Perf YTD15.20%
Dividend- P/FCF- EPS past 5Y-12.80% ROI-41.20% 52W High-39.74% Beta0.57
Dividend %- Quick Ratio10.40 Sales past 5Y-27.90% Gross Margin- 52W Low39.88% ATR0.14
Employees126 Current Ratio10.40 Sales Q/Q- Oper. Margin- RSI (14)62.40 Volatility6.55% 6.26%
OptionableYes Debt/Eq0.02 EPS Q/Q7.00% Profit Margin- Rel Volume1.67 Prev Close2.30
ShortableYes LT Debt/Eq0.01 EarningsApr 28 BMO Payout- Avg Volume79.00K Price2.35
Recom1.30 SMA2010.89% SMA509.72% SMA200-4.52% Volume131,665 Change2.17%
Date Action Analyst Rating Change Price Target Change
Feb-01-19Downgrade UBS Buy → Neutral
Jan-04-19Initiated UBS Buy
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
May-04-23 09:02AM
Apr-28-23 07:14AM
Apr-26-23 08:01PM
Apr-07-23 08:29AM
07:00AM Loading…
Apr-05-23 07:00AM
Mar-20-23 08:00AM
Mar-16-23 07:00AM
Mar-08-23 07:00AM
Feb-07-23 07:00AM
Feb-02-23 08:15AM
Jan-27-23 09:57AM
Jan-26-23 07:00AM
Jan-18-23 07:00AM
Jan-07-23 08:45AM
07:00AM Loading…
Nov-30-22 07:00AM
Nov-25-22 07:17AM
Nov-23-22 07:30AM
Nov-08-22 07:58AM
Oct-29-22 08:06AM
Oct-28-22 09:25AM
Oct-04-22 08:36AM
Sep-26-22 07:30AM
Sep-01-22 08:00AM
Aug-24-22 04:05PM
Aug-11-22 07:30AM
Aug-02-22 11:00AM
Jul-31-22 08:12AM
Jul-28-22 08:45AM
07:30AM Loading…
Jul-22-22 07:30AM
Jun-24-22 04:30PM
Jun-21-22 10:35AM
Jun-17-22 08:31AM
Jun-16-22 08:20AM
Jun-01-22 08:26AM
May-31-22 07:30AM
May-17-22 09:00AM
May-09-22 11:00AM
Apr-28-22 07:30AM
Apr-27-22 07:55AM
Apr-08-22 07:30AM
Mar-30-22 07:58AM
Mar-22-22 07:30AM
Mar-21-22 07:30AM
Mar-16-22 07:41AM
Feb-28-22 07:30AM
Feb-21-22 04:30AM
Feb-15-22 02:54PM
Feb-04-22 07:30AM
Feb-02-22 08:58AM
Dec-15-21 07:49AM
Nov-15-21 06:01AM
Nov-12-21 08:21AM
Nov-10-21 11:20AM
Nov-08-21 08:25AM
Nov-07-21 07:53AM
Nov-05-21 03:00PM
Nov-04-21 06:00AM
Nov-02-21 07:30AM
Oct-29-21 06:00AM
Oct-25-21 07:00AM
Oct-24-21 08:04AM
Sep-03-21 07:52AM
Sep-02-21 07:00AM
Sep-01-21 11:30AM
Aug-31-21 04:03PM
Aug-04-21 08:25AM
Jul-29-21 07:30AM
Jul-28-21 03:03PM
Jul-27-21 09:27AM
Jul-26-21 01:22AM
Jun-25-21 08:38AM
Jun-02-21 07:34AM
May-27-21 01:11AM
May-20-21 07:00AM
May-17-21 09:55AM
Apr-28-21 08:45AM
Apr-20-21 12:00PM
Mar-31-21 07:00AM
Mar-28-21 03:00AM
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.